NCT02370589View on ClinicalTrials.gov

Study to Evaluate the Immunogenicity and Safety of an Ebola Virus (EBOV) Glycoprotein (GP) Vaccine in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

230

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Ebola
Interventions
BIOLOGICAL

Base Dose EBOV GP Vaccine

BIOLOGICAL

2x Base Dose EBOV GP Vaccine

BIOLOGICAL

4x Base Dose EBOV GP Vaccine

BIOLOGICAL

8x Base Dose EBOV GP Vaccine

BIOLOGICAL

Placebo

BIOLOGICAL

Matrix-M Adjuvant

Trial Locations (3)

3004

Nucleus Network, Melbourne

4006

Q-Pharm Pty Ltd., Brisbane

6009

Linear Clinical Research, Nedlands

Sponsors

Lead Sponsor

Novavax
All Listed Sponsors
lead

Novavax

INDUSTRY

NCT02370589 - Study to Evaluate the Immunogenicity and Safety of an Ebola Virus (EBOV) Glycoprotein (GP) Vaccine in Healthy Subjects | Biotech Hunter | Biotech Hunter